SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant (Q493R)-Fc tag

Reference:
Product nameSARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant (Q493R)-Fc tag
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Sequence  YP_009724390.1
Molecular weight65kDa
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB,,,
Fragment TypeSpike protein fragment
Aliases /SynonymsB.1.1.529, Omicron variant, lineage B.1.1.529, South Africa variant, Botswana variant, mutation Q493R
ReferencePX-COV-P075
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

General information on SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant (Q493R)

In November 2021 a new variant was reported in South Africa. This Lineage B.1.1.529 was given the name Omicron. This variant has a remarkable high number of mutations including uncommon mutation especially located in the Receptor Binding domain (RBD).
The reported mutations are the following : A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211-212, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.
Mutations K417N and N501Y had previously been reported in Beta variant from South Africa. S477N was typically found in lineage B.1.526.2.
On site 493, both amino-acids lysine and arginine have been reported. Proteogenix offers both RBD variants (PX-COV-P074 for Q493K, PX-COV-P075 for Q493R).
Although this variant was first reported in South Africa in November 2021, by the end of December 2021 it had reached every continents, soon replacing the other variants in the majority of detected covid cases. For example, in the USA, three positive covid tests out of 4 reported the Omicron as the variant by the 21st of December. The WHO stated this variant as Variant of Concern (VOC) along with the beta, gamma and delta variants.
Studies are still going on to evaluate the virulence of this variant. Moreover, the first insights show a higher reinfection rate than for previous variants.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant (Q493R)-Fc tag”

Your email address will not be published. Required fields are marked *

Related products

Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1031 400€
Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1032 400€
Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
Biosimilar Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade PX-TA1033 300€
Sotrovimab  Biosimilar – Anti-Spike glycoprotein mAb – Research Grade
Biosimilar Sotrovimab Biosimilar – Anti-Spike glycoprotein mAb – Research Grade PX-TA1637 400€
Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade
Biosimilar Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade PX-TA1750 400€
Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Beludavimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1797 400€
Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Upanovimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1798 400€
Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Amubarvimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1799 400€
Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade
Biosimilar Romlusevimab Biosimilar – Anti-Spike RBD mAb – Research Grade PX-TA1800 400€
Anti-RBD-4 antibody (Casirivimab)
Biosimilar Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552 300€
Anti-RBD-5 antibody (Imdevimab)
Biosimilar Anti-RBD-5 antibody (Imdevimab) PTXCOV-A553 300€
Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab)
SIL Stable Isotope Labeled Anti-RBD-4 antibody (Casirivimab) PTXCOV-A552-SIL 1500€
Anti-2019-nCoV(S1) – 2 (H4) antibody
Monoclonal Antibody Anti-2019-nCoV(S1) – 2 (H4) antibody PTXCOV-A514 300€
Anti-2019-nCoV(S1)-1 IgM antibody
Monoclonal Antibody Anti-2019-nCoV(S1)-1 IgM antibody PTXCOV-A542 380€
ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740)
Receptor ACE2 protein – Soluble ectodomain of human ACE-2 (aa 1-740) PX-COV-P048 185€

Contact us

Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.